Science Oriented Solutions (SOS) and Clinical Solutions (CS), Publicis Healthcare Communications Group (PHCG) companies, today announced the successful completion of merging their operations.
Atlanta, Georgia -- April 6, 2005 -- Science Oriented Solutions (SOS) and Clinical Solutions (CS), Publicis Healthcare Communications Group (PHCG) companies, today announced the successful completion of merging their operations. President and Chief Operating Officer of SOS Evan Demestihas, M.D., RPh. will oversee the joint operation.
"Merging the two operations follows a natural synergy that will enable them to expand the range of services they provide to their clients," said Dr. Demestihas.
SOS, founded in 1997, is the first and leading contract medical affairs organization providing outsourcing for essential medical affairs activities. SOS is widely recognized as the sector leader in providing contract medical science liaison services. CS, in operation since 1994, is an integrated marketing agency that creates and implements clinical trial marketing communications and strategies that are protocol-specific and optimize patient recruitment and retention. SOS and Clinical Solutions share office space in Kennesaw, Georgia, a suburb of Atlanta.
While each company will maintain its individual pharmaceutical and biotech client base, Dr. Demestihas adds, "The merging of SOS and CS operations allows for a broader spectrum of services as well as an increase in management support, additional creative capabilities, and enhanced call center services."
About Science Oriented Solutions (SOS)
SOS, a full-service commercial-side medical affairs group, was established in 1997 as the pharmaceutical industry's first Contract Medical Organization (CMO). SOS focuses on delivering comprehensive outsourcing of medical affairs activities, including Medical Science Liaison (MSL) and medical communications services to pharmaceutical, biotechnology and medical device companies and integrates its activities with the client's core commercial and marketing objectives.
Clinical Solutions, in operation since 1994, is an integrated marketing company exclusively focused on optimizing patient recruitment and retention for clinical trials in a wide range of therapeutic areas. CS is known for developing and implementing protocol-specific programs for pharmaceutical, biotechnology, and medical device companies that are strategic, creative and results oriented.
About Publicis Healthcare Communications Group (PHCG)
Publicis Healthcare Communications Group (PHCG), a member of Publicis Groupe S.A., is the largest healthcare communications group in the world. Worldwide healthcare services include Advertising, Medical Education, Sales and Marketing, Medical and Scientific Affairs, and Healthcare Consulting. PHCG offers its clients a strategic partnership, a strong focus on ensuring value for their marketing spend, and exceptional performance on their assignments.
Publicis Groupe (Euronext Paris: 13057, NYSE: PUB) is the world's fourth largest communications group, and a world leader in media counsel and buying. Services are provided in 109 countries on six continents.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.